Opinion|Videos|March 11, 2025
When to Move Beyond TACE: The Expanding Role of Systemic Therapy in Intermediate-Stage HCC
Author(s)Richard S. Finn, MD, Amit Singal, MD
Panelists discuss how combining systemic therapy with locoregional treatments like transarterial chemoembolization (TACE) aims to enhance therapeutic efficacy by addressing its limitations, such as incomplete tumor necrosis and hypoxia-induced progression. Tyrosine kinase inhibitors (TKIs) like lenvatinib and immune checkpoint inhibitors (ICIs) counteract TACE-induced resistance by inhibiting angiogenesis and boosting immune response, improving overall tumor control.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In recent years, several trials have sought to evaluate the potential synergy of combining systemic therapy with locoregional therapy. Please discuss the rationale for combining systemic therapy with locoregional treatments like TACE.
- What are the limitations of TACE monotherapy?
- How do TKIs like lenvatinib or ICIs contribute to overcoming TACE-induced tumor progression/resistance mechanisms?
- How does this combination potentially enhance treatment efficacy compared with TACE alone?
Advertisement
Related to this article
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
4
How Patient Factors Steer Treatment Selection in Metastatic Melanoma
5